Waters Corporation’s Market Position and Recent Performance Metrics

Waters Corporation (WAT), based in Milford, Massachusetts, stands out as a prominent player in analytical instruments and laboratory solutions worldwide. With a market capitalization of $22.2 billion, the company specializes in technologies such as liquid chromatography (LC), mass spectrometry (MS), and thermal analysis, catering to sectors including pharmaceuticals, life sciences, food safety, environmental testing, and material sciences.

Fitting the profile of a large-cap stock, Waters, with its market cap exceeding $10 billion, underscores its significant influence within the diagnostics and research industries.

Active Investor: FREE newsletter going behind the headlines on the hottest stocks to uncover new trade ideas

 

The company’s advanced instruments and software facilitate precise chemical analysis and molecular detection, crucial for drug development, quality control, and scientific exploration. With a commitment to innovation, sustainability, and data-informed strategies, Waters Corporation continues to expand its global presence while enhancing laboratory efficiencies through cutting-edge analytical solutions and digital transformation initiatives.

Despite its strong fundamentals, WAT experienced a 13% decline from its 52-week peak of $423.56, recorded on January 10. In the last three months, WAT’s stock has risen by 1.2%, lagging behind the Health Care Select Sector SPDR Fund (XLV), which gained 4.3% during the same period.

Over a six-month horizon, shares of WAT have declined by 4.8%, underperforming compared to XLV’s 10.7% growth. However, looking back at 52 weeks, WAT bounced back with a 7.5% increase, surpassing XLV’s minimal returns over the same timeframe.

WAT has maintained a trading position above its 200-day moving average since late July, although it has remained under its 50-day moving average since mid-February.

WAT shares fell more than 5% on February 12 after the release of its Q4 results. The company reported an adjusted EPS of $4.10, exceeding Wall Street’s expectation of $4.02. Its revenue reached $872.7 million, outperforming forecasts of $857.1 million.

Dr. Udit Batra, President & CEO of Waters Corporation, credited the company’s strong showing to “double-digit growth in Pharma,” noting high single-digit growth in both instruments and recurring revenue in constant currency. He highlighted strategic initiatives and operational execution as key factors driving this success. WAT anticipates a full-year adjusted EPS ranging from $12.70 to $13.

In contrast, Waters’ competitor, Agilent Technologies, Inc. (A), has underperformed with a 13.6% decline over the past six months and a 17.2% drop over the last 52 weeks.

Despite some uncertainty, Wall Street analysts maintain a cautious view on WAT’s future. The stock holds a consensus “Moderate Buy” rating from 18 analysts, with a mean price target of $405.65, indicating a potential upside of 10.1% from current levels.

On the date of publication,

Kritika Sarmah

did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information, please view the Barchart Disclosure Policy

here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.